Prognostic variable | Hazard ratio | 95% CI | P (χ2 test) |
---|---|---|---|
Univariable survival analysis (all eligible patients who started with definitive chemoradiotherapy [n = 92]) | |||
MTVpost | 1.042 | 1.007–1.079 | 0.017 |
SUVmax(post) | 1.486 | 1.062–2.080 | 0.043 |
TLGmax(post) | 1.028 | 1.009–1.048 | 0.0044 |
Multivariable survival analysis (all eligible patients [n = 92]) | |||
Total radiation dose | 0.930 | 0.902–0.959 | <0.0001 |
TLGmax(post) | 1.032 | 1.013–1.052 | 0.0002 |
Multivariable survival analysis (all patients who received at least 60-Gy total dose [n = 85]) | |||
Total radiation dose | 0.891 | 0.813–0.977 | 0.0142 |
TLGmax(post) | 1.034 | 1.014–1.054 | 0.0008 |
Multivariable time to progression analysis (all patients who received at least 60-Gy total dose [n = 85]) | |||
TLGmax(post) | 1.038 | 1.018–1.058 | 0.0001 |
Total radiation dose | 0.848 | 0.770–0.934 | 0.0008 |
Multivariable time to distant progression alone analysis (all patients who received at least 60 Gy total dose [n = 85]) | |||
TLGmax(post) | 1.037 | 1.014–1.061 | 0.0018 |
Multivariable time to locoregional progression as component of first relapse analysis (all patients who received at least 60-Gy total dose [n = 85]) | |||
Total radiation dose | 0.807 | 0.705–0.924 | 0.0019 |
cT3 tumor category | 3.605 | 1.326–9.800 | 0.012 |
SUVmax(post) | 1.070 | 1.003–1.141 | 0.039 |
All clinical and PET parameters listed in Table 1 were included in analysis. Hazard ratios are given per 10 cm3 increase in MTV, or per SUVmax increase of 10, or per TLG increase of 100 cm3.